Loading...

Helix BioPharma Corp.

HBP.TOTSX
Healthcare
Biotechnology
CA$1.47
CA$0.12(8.89%)

Helix BioPharma Corp. (HBP.TO) Stock Competitors & Peer Comparison

See (HBP.TO) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
HBP.TOCA$1.47+8.89%109M-1.43-CA$1.03N/A
BLU.TOCA$19.48-0.10%2.5B-20.29-CA$0.96N/A
MMED.NECA$14.90+9.48%1.1B-4.50-CA$3.31N/A
DRUG.CNCA$58.56-2.43%414.8M-42.74-CA$1.37N/A
FRX.TOCA$12.16+1.84%334.1M-19.61-CA$0.62N/A
EPRX.TOCA$7.20-1.77%258.8M-6.05-CA$1.19N/A
CYBN.NECA$10.07+2.23%237.6M-1.64-CA$6.15N/A
BCT.TOCA$10.41+9.58%182.7M-0.10-CA$106.70N/A
ONC.TOCA$1.42+2.16%142.3M-3.84-CA$0.37N/A
MSCL.TOCA$0.60+1.69%105.7M2.31CA$0.26N/A
Showing 1 to 10 of 59 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

HBP.TO vs BLU.TO Comparison August 2025

HBP.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HBP.TO stands at 109M. In comparison, BLU.TO has a market cap of 2.5B. Regarding current trading prices, HBP.TO is priced at CA$1.47, while BLU.TO trades at CA$19.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HBP.TO currently has a P/E ratio of -1.43, whereas BLU.TO's P/E ratio is -20.29. In terms of profitability, HBP.TO's ROE is +13.32%, compared to BLU.TO's ROE of -0.22%. Regarding short-term risk, HBP.TO is more volatile compared to BLU.TO. This indicates potentially higher risk in terms of short-term price fluctuations for HBP.TO.Check BLU.TO's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;